Article
Immunology
Daqin Chen, Zhaojia Ye, Zhenfei Pi, Satoshi Mizukami, Kiyoshi Aoyagi, Yawen Jiang
Summary: The study provides evidence that dual influenza and pneumococcal vaccination is a cost-effective disease prevention strategy for the elderly in Shenzhen, China. It significantly reduces the incidence of influenza and pneumococcal infections and achieves good cost-effectiveness within 5 years.
Review
Immunology
Claire Froneman, Peter Kelleher, Ricardo J. Jose
Summary: Infections with Streptococcus pneumoniae are a common cause of morbidity and mortality worldwide, especially affecting those at the extremes of age and immunocompromised individuals. Preventing pneumococcal disease is crucial in at-risk individuals, and pneumococcal vaccination should be offered to them.
Review
Microbiology
Nobuhiro Asai, Hiroshige Mikamo
Summary: Pneumococcal disease is a global burden with high mortality rates. The use of pneumococcal vaccines in children has been effective, but vaccination for at-risk individuals aged 19-64 requires careful consideration due to insufficient evidence.
Article
Biotechnology & Applied Microbiology
Norman Rose, Josephine Storch, Anna Mikolajetz, Thomas Lehmann, Konrad Reinhart, Mathias W. Pletz, Christina Forstner, Horst Christian Vollmar, Antje Freytag, Carolin Fleischmann-Struzek
Summary: In the elderly, influenza and pneumococcal vaccinations can respectively reduce the risk of laboratory-confirmed influenza, pneumonia, and sepsis. However, vaccine effectiveness varies by year and season, and there are still some phenomena that are difficult to explain.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Jung Yeon Heo, Yu Bin Seo, Won Suk Choi, Eun Jin Kim, Hye Won Jeong, Jacob Lee, Jin Gu Yoon, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Joon Young Song
Summary: The effectiveness of pneumococcal vaccines against pneumococcal pneumonia is low in the elderly. However, sequential PCV13/PPSV23 vaccination shows the highest effectiveness in the younger subgroup.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Nursing
Joseph Walter, Nicole Rudawsky
Summary: This article reviews the updated pneumococcal vaccine recommendations from the Centers for Disease Control and Prevention, including two new vaccines, and discusses their advantages, disadvantages, and nursing implications.
AMERICAN JOURNAL OF NURSING
(2023)
Article
Mathematics, Interdisciplinary Applications
Humaira Yasmin
Summary: Pneumococcal pneumonia is a contagious and potentially fatal bacterial lung infection. It is crucial to conceptualize the transmission of this infection and provide control interventions. In this study, an epidemic model was developed to understand the transmission phenomena of pneumococcal pneumonia. The equilibria and reproduction parameter of the model were determined, and stability results were proved. Numerical analysis was conducted to analyze the reproduction parameters under different input parameters. The study also discussed the dynamic behavior of the system to develop effective infection control policies and recommended factors for reducing pneumococcal pneumonia to policymakers in the community.
CHAOS SOLITONS & FRACTALS
(2022)
Article
Pediatrics
Jian-Te Lee, Jou-Wei Lin, Ho-Min Chen, Chen-Yu Wang, Chun-Yi Lu, Luan-Yin Chang, Li-Min Huang
Summary: This study found that the national PCV13 vaccination program in Taiwan reduced the incidence rates of pneumococcal parapneumonic diseases and lobar/pneumococcal pneumonia, as well as the intensity of pneumonia care and mortality across all age groups.
PEDIATRIC RESEARCH
(2022)
Article
Critical Care Medicine
Samuel Rhedin, Cecilia Lundholm, Emma Caffrey Osvald, Catarina Almqvist
Summary: This study found that children diagnosed with pneumonia in infancy have a significantly increased risk for developing asthma at the age of 4, and this association remains even after the introduction of pneumococcal conjugate vaccine immunization.
Article
Multidisciplinary Sciences
Deus Thindwa, Samuel Clifford, Jackie Kleynhans, Anne von Gottberg, Sibongile Walaza, Susan Meiring, Todd D. Swarthout, Elizabeth Miller, Peter McIntyre, Nick Andrews, Zahin Amin-Chowdhury, Norman Fry, Kondwani C. Jambo, Neil French, Samanta Cristine Grassi Almeida, Shamez N. Ladhani, Robert S. Heyderman, Cheryl Cohen, Maria Cristina de Cunto Brandileone, Stefan Flasche
Summary: The risk of invasive pneumococcal disease (IPD) increases with age for older adults, but the population benefiting from pneumococcal vaccines and the immunogenic response to vaccination decline. This study examined the impact of demographics, vaccine efficacy, and waning efficacy on the optimal age for pneumococcal vaccination. The findings suggest that administering pneumococcal vaccines earlier in adulthood in low/middle-income countries could prevent a significant proportion of residual IPD burden.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Phoebe Wellmann, Christian Kromer, Ralf Siemer, Selina Klein, Johannes Mohr, Undine Lippert, Andreas Pinter, Dagmar Wilsmann-Theis, Rotraut Moessner
Summary: The pneumococcal vaccination rate is low among PsO and AD patients in Germany, with PsO patients having a slightly higher rate. Lack of recommendation from physicians is the most common reason for nonvaccination.
Article
Microbiology
Thomas Chandler, Stephen Furmanek, Ruth Carrico, Dawn Balcom, Forest Arnold, Julio Ramirez
Summary: This study analyzed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for preventing hospitalization due to serotype-specific community-acquired pneumonia (CAP). The results showed that PPSV23 did not offer protection against CAP hospitalization caused by the vaccine-contained serotypes. This study highlights the importance of developing more effective vaccines for the prevention of hospitalization due to S. pneumoniae CAP.
Article
Multidisciplinary Sciences
Adam J. Streeter, Lauren R. Rodgers, Jane Masoli, Nan X. Lin, Alessandro Ble, Willie Hamilton, William E. Henley
Summary: The research found that the 23-valent pneumococcal polysaccharide vaccine (PPV23) has a moderate effectiveness in reducing the risk of community-acquired pneumonia (CAP) among UK patients aged 65 and above in the two years after vaccination. The effectiveness of the vaccine is maintained and may increase in the oldest age groups as their susceptibility to CAP increases.
Article
Oncology
Chung-Yi Li, Liang-Cheng Chen, Hon-Yi Lin, Moon-Sing Lee, Shih-Kai Hung, Chun-Liang Lai, Li-Wen Huang, Ben-Hui Yu, Feng-Chun Hsu, Wen-Yen Chiou
Summary: Vaccination of elderly patients with prostate cancer using PPSV23 significantly decreases the risk of bacterial pneumonia hospitalizations and improves overall survival in Taiwan.
Article
Immunology
Maria Morales-Suarez-Varela, Diana Toledo, Maria Amelia Fernandez-Sierra, Maria Liebana, Gerardo Rubiera, Gema Navarro, Concepcion Prados, Judith Chamarro, Isabel Peraita-Costa, Angela Dominguez
Summary: This retrospective cohort study found that individuals who were vaccinated against pneumococcal disease had a lower risk of developing SARS-CoV-2 pneumonia compared to those who were not vaccinated. The study also identified certain high-risk groups for developing SARS-CoV-2 pneumonia, such as individuals with obesity, diabetes, and respiratory diseases, who could potentially benefit from vaccination and monitoring.
